The Price of Global Health is a unique book that describes the pharmaceutical pricing process and its business, economic and social challenges. Global drug pricing is one of the most hotly debated yet least understood aspects of the pharmaceutical industry. How should drug prices be set and what does it mean for patients? Why do governments increasingly get involved, and what is its impact on the global competitive environment? How can a life-saving industry have a poorer image than gun and tobacco industries, whose products are associated with death?

The pharmaceutical industry is under unprecedented pressure due to a combination of declining R&D productivity, payer/provider demands for better value and public pressures to show pricing restraint. Rapidly increasing cost of healthcare, shifts from fee-for-service to value-based reimbursement, public pressure on drug pricing and an increasingly vocal medical community have empowered public and private payers worldwide to be more demanding on evidence of value for the prescription drugs that are brought to market. Pharmaceutical companies have often failed to deliver evidence of patient value, as development decision-making is overly focused on speed to FDA approval rather than speed to commercial success by effectively addressing the many “Access Journey” obstacles that typify today’s much changed pharmaceutical environment.

This 3rd edition is significantly expanded with ten new chapters and revised and updated throughout to reflect today’s environment. The contents are reorganized to directly address critical pricing and patient access issues. Ed Schoonveld explains how pharmaceutical prices are determined in a complex global payer environment and what factors influence the process. His insights will help a wide range of audiences from healthcare industry professionals to policy makers, consumers, pharmaceutical company leaders and access and pricing professionals to gain a better understanding of this highly complex and emotionally charged field.

part A|60 pages

The challenges of drug pricing

chapter 1|28 pages

Why is drug pricing different?

chapter 2|10 pages

The age of value and affordability

chapter 3|10 pages

The Access Journey

chapter 4|11 pages

Fair pricing

part B|32 pages

Traveling the Access Journey

chapter 5|12 pages


chapter 6|7 pages

Medical community

chapter 7|5 pages

Provider organizations

chapter 8|4 pages


part C|54 pages

Pricing and payer management techniques

chapter 9|16 pages

Fundamentals of pricing

chapter 10|8 pages

Reference-based pricing

part D|112 pages

Structured access and pricing approaches

chapter 13|24 pages

Pricing and drug development

chapter 14|20 pages

Payer segmentation

chapter 15|11 pages

The PODiUM framework

chapter 16|26 pages

BEST framework

chapter 18|19 pages

Value story and messaging

part E|87 pages

Developing an integrated global strategy

chapter 20|13 pages

Public policy

chapter 21|12 pages

Oncology and orphan drugs

chapter 22|6 pages

Gene and cell therapies

chapter 23|5 pages


chapter 24|24 pages

Payer and pricing research

part F|45 pages

Access and pricing strategy implementation

chapter 25|12 pages

Organizing for access

chapter 26|12 pages

Access and price negotiations

chapter 27|12 pages

Value-based agreements

chapter 28|8 pages

Creating win-win partnerships

part G|157 pages

Key healthcare systems

chapter 29|31 pages

United States

chapter 30|13 pages


chapter 31|12 pages


chapter 32|13 pages


chapter 33|12 pages


chapter 34|7 pages


chapter 35|9 pages

United Kingdom

chapter 36|15 pages


chapter 37|5 pages


chapter 38|7 pages


chapter 39|5 pages


chapter 40|9 pages


chapter 41|8 pages

South Korea